ResearcherCentre National de la Recherche ScientifiqueNo recent work listed
Ulrich Nitsche
Matched on ORCID iD 0000-0002-8501-5652; OpenAlex author ID A5015962203. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper
Papers 8
- Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and… Co-author DOI 10.1186/s12885-018-4055-9↗
- IL-4 mRNA Is Downregulated in the Liver of Pancreatic Cancer Patients Suffering from Cachexia. Co-author DOI 10.1080/01635581.2017.1247885↗
- Contemporary strategies to improve the outcome in locally advanced pancreatic cancer. Co-author DOI 10.23736/s0026-4733.17.07410-7↗
- Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? Co-author DOI 10.4103/0971-5851.195731↗
- A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Co-author DOI 10.1038/srep08109↗
- Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Co-author DOI 10.1245/s10434-015-4851-2↗
- Strategies to improve the outcome in locally advanced pancreatic cancer. First author PMID 25658301↗
- Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. First author DOI 10.1158/1535-7163.mct-11-0006↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jorg H. Kleeff · 6 shared papers, 2011–2017 · strength 0.34
- Paper Contemporary strategies to improve the outcome in locally advanced pancreatic cancer. DOI 10.23736/s0026-4733.17.07410-7↗
- Paper Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? DOI 10.4103/0971-5851.195731↗
- Paper Strategies to improve the outcome in locally advanced pancreatic cancer. PMID 25658301↗
- Mert Erkan · 4 shared papers, 2015–2017 · strength 0.24
- Paper Contemporary strategies to improve the outcome in locally advanced pancreatic cancer. DOI 10.23736/s0026-4733.17.07410-7↗
- Paper Strategies to improve the outcome in locally advanced pancreatic cancer. PMID 25658301↗
- Paper A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high en… DOI 10.1038/srep08109↗
- Helmut Friess · 4 shared papers, 2011–2018 · strength 0.23
- Paper Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia i… DOI 10.1186/s12885-018-4055-9↗
- Paper Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? DOI 10.4103/0971-5851.195731↗
- Paper A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high en… DOI 10.1038/srep08109↗
- Bo Kong · 4 shared papers, 2015–2016 · strength 0.22
- Paper Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? DOI 10.4103/0971-5851.195731↗
- Paper Strategies to improve the outcome in locally advanced pancreatic cancer. PMID 25658301↗
- Paper A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high en… DOI 10.1038/srep08109↗
- Marc Eric Martignoni · 2 shared papers, 2017–2018 · strength 0.16
- Olga Prokopchuk · 2 shared papers, 2017–2018 · strength 0.16
- Christoph W. Michalski · 3 shared papers, 2015 · strength 0.15
- Paper Strategies to improve the outcome in locally advanced pancreatic cancer. PMID 25658301↗
- Paper A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high en… DOI 10.1038/srep08109↗
- Paper Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center… DOI 10.1245/s10434-015-4851-2↗
- Christoph Späth · 2 shared papers, 2015–2017 · strength 0.15
- Helmut Frieß · 2 shared papers, 2015–2017 · strength 0.12
- Iréne Esposito · 2 shared papers, 2015 · strength 0.09
- Paper A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high en… DOI 10.1038/srep08109↗
- Paper Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center… DOI 10.1245/s10434-015-4851-2↗
- Rick Schneider · 1 shared paper, 2017 · strength 0.09
- Achim Krüger · 1 shared paper, 2018 · strength 0.08
- Barbara T. Grünwald · 1 shared paper, 2018 · strength 0.08
- Jeannine Bachmann · 1 shared paper, 2017 · strength 0.07
- Konstantin Holzapfel · 1 shared paper, 2015 · strength 0.04
- Anna Melissa Schlitter · 1 shared paper, 2015 · strength 0.04
- Jens Thomas Siveke · 1 shared paper, 2015 · strength 0.04
- Rickmer Braren · 1 shared paper, 2015 · strength 0.04
- Matthias Maak · 1 shared paper, 2011 · strength 0.02
- Klaus‐Peter Janssen · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.